RARE Ultragenyx Pharmaceutical Inc

Price (delayed)

$28.76

Market cap

$2.83B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.1

Enterprise value

$3.86B

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 23

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of ...

Highlights
The revenue rose by 13% year-on-year
The company's gross profit rose by 11% YoY
The equity has dropped by 179% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 35% YoY

Key stats

What are the main financial stats of RARE

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
-0.93%
1 week
15.73%
1 month
22.96%
1 year
-21.91%
YTD
25.04%
QTD
37.28%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$669.71M
Gross profit
$559.37M
Operating income
-$561.06M
Net income
-$608.92M
Gross margin
83.5%
Net margin
-90.9%
The revenue rose by 13% year-on-year
The company's gross profit rose by 11% YoY
Ultragenyx Pharmaceutical's net income has decreased by 11% YoY and by 6% QoQ
The operating income fell by 9% YoY and by 4.9% QoQ

Price vs fundamentals

How does RARE's price correlate with its fundamentals

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
N/A
P/S
4.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.76
RARE's EPS is down by 4.6% since the previous quarter and by 3.9% year-on-year
The equity has dropped by 179% since the previous quarter
The P/S is 53% lower than the 5-year quarterly average of 9.1
The revenue rose by 13% year-on-year

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
The return on assets has declined by 24% year-on-year and by 6% since the previous quarter
The company's return on invested capital fell by 17% YoY and by 2.4% QoQ
RARE's return on sales is down by 7% since the previous quarter but it is up by 2.4% year-on-year

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 15% less than the total liabilities
The company's total liabilities rose by 31% YoY but it fell by 5% QoQ
The quick ratio has decreased by 25% QoQ and by 19% YoY
The equity has dropped by 179% since the previous quarter
Ultragenyx Pharmaceutical's debt to equity has plunged by 176% YoY but it has soared by 65% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.